Literature DB >> 3709595

Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.

A Gouyette, A Apchin, M Foka, J M Richard.   

Abstract

After administration of cisplatin (50 mg/m2 on days 1 and 2) by intra-arterial or intravenous infusions over 1 or 6 hr to a total of 24 patients with head and neck cancer, the main pharmacokinetic parameters of platinum were determined according to a multicompartmental analysis. Elimination half-life of total platinum is greater than 3 days, the amount of platinum recovered in the urine over 7 days accounting for 15-50% of the administered dose. The half-life of filterable platinum species was calculated from the urinary excretion data: 39 +/- 17 min (i.a./1 hr), 37 +/- 24 min (i.a./6 hr), 58 +/- 17 min (i.v./1 hr) and 51 +/- 22 min (i.v./6 hr). Biopsies of the tumor were also analyzed on day 3 for their platinum content. The mean concentrations of platinum in biopsies were: 2.72 micrograms/g (i.a./1 hr), 3.89 micrograms/g (i.a./6 hr), 1.27 micrograms/g (i.v./1 hr) and 1.38 micrograms/g (i.v./6 hr). Tumor regression, based upon clinical and histological data, was only moderate after this single chemotherapy course.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709595     DOI: 10.1016/0277-5379(86)90389-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  11 in total

1.  Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients.

Authors:  J L Pujol; D Cupissol; C Gestin-Boyer; J Bres; B Serrou; F B Michel
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Flavone acetic acid: a nonlinear pharmacokinetic model.

Authors:  A Gouyette; D J Kerr; S B Kaye; A Setanoians; J Cassidy; C Bradley; G Forrest; M Soukop
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.

Authors:  S S Bielack; R Erttmann; G Looft; C Purfürst; G Delling; K Winkler; G Landbeck
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Pharmacokinetics and tumor concentration of intraarterial and intravenous cisplatin in patients with head and neck squamous cancer.

Authors:  V C Sileni; V Fosser; P Maggian; E Padula; M Beltrame; M Nicolini; P Arslan
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

Authors:  S Sugimoto; Y L Yamamoto; S Nagahiro; M Diksic
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

6.  Disposition and tumour concentrations of platinum in hypoalbuminaemic patients after treatment with cisplatin for cancer of the head and neck.

Authors:  J D Holding; W E Lindup; D A Bowdler; M Z Siodlak; P M Stell
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

7.  Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.

Authors:  G Los; f A Blommaert; R Barton; D D Heath; L den Engelse; C Hanchett; D Vicario; R Weisman; K T Robbins; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Treatment outcome of maxillary sinus cancer.

Authors:  Hye Sung Won; Sang Hoon Chun; Bum-Soo Kim; So Ryoung Chung; Ie Ryung Yoo; Chan-Kwon Jung; Yeon-Sil Kim; Dong-Il Sun; Min Sik Kim; Jin-Hyoung Kang
Journal:  Rare Tumors       Date:  2009-12-28

9.  Laser-assisted delivery enhances topical uptake of the anticancer agent cisplatin.

Authors:  Emily Wenande; Uffe H Olesen; Malene R Boesen; Daniel P Persson; Catharina M Lerche; Stefan Stürup; Bente Gammelgaard; Søren Husted; R Rox Anderson; Merete Haedersdal
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

10.  Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Authors:  F J P Hoebers; D Pluim; A A M Hart; M Verheij; A J M Balm; G Fons; C R N Rasch; J H M Schellens; L J A Stalpers; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-18       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.